Last reviewed · How we verify
[68Ga]CBP8 PET/MRI
This drug is a radiopharmaceutical that targets the PSMA protein.
This drug is a radiopharmaceutical that targets the PSMA protein. Used for Prostate cancer diagnosis and imaging.
At a glance
| Generic name | [68Ga]CBP8 PET/MRI |
|---|---|
| Also known as | No other names |
| Sponsor | Brigham and Women's Hospital |
| Drug class | Radiopharmaceutical |
| Target | PSMA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It is used in PET/MRI imaging to visualize and diagnose prostate cancer. The [68Ga]CBP8 compound binds to PSMA, allowing for the detection of PSMA-expressing cells in the body.
Approved indications
- Prostate cancer diagnosis and imaging
Common side effects
- Radiation exposure
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- [68Ga]CBP8 PET/MRI CI brief — competitive landscape report
- [68Ga]CBP8 PET/MRI updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI